Premium
Histologically proven non‐alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation
Author(s) -
Kim Hyeyoung,
Lee Kyoungbun,
Lee KwangWoong,
Yi NamJoon,
Lee Hae Won,
Hong Geun,
Choi YoungRok,
You Tae,
Suh SukWon,
Jang Ja June,
Suh KyungSuk
Publication year - 2014
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.12343
Subject(s) - medicine , steatosis , fatty liver , steatohepatitis , liver transplantation , gastroenterology , alcoholic liver disease , odds ratio , liver biopsy , population , metabolic syndrome , cirrhosis , risk factor , biopsy , transplantation , obesity , disease , environmental health
Non‐alcoholic fatty liver disease ( NAFLD ) affects a substantial proportion of the world population, and its prevalence has been increasing. The study was aimed at evaluating the prevalence and peri‐transplant risk factors for post‐liver transplantation ( LT ) NAFLD . A retrospective review was performed for adult recipients who underwent late protocol biopsy (>1 yr after LT ) between August 2010 and December 2012. Hepatic steatosis was reviewed and graded by hepatopathologists, and the peri‐transplant factors were analyzed for relationships to histologically proven NAFLD . Total 166 biopsies had been performed in 156 recipients. NAFLD was present in 27.1% at a mean period of 35.4 months between LT and biopsy, moderate and severe steatosis (≥33%) consisted of 28.9%. In multivariate analysis, pre‐ LT alcoholic cirrhosis (odds ratio [ OR ] 8.031, p = 0.003), obesity at biopsy ( OR 3.873, p = 0.001), and preexisting donor graft steatosis ( OR 3.147, p = 0.022) were significant risk factors for post‐ LT NAFLD . In conclusion, NAFLD represented a considerable portion of recipients, but this prevalence was not higher than those for general population. Three risk factors were significantly related to post‐ LT NAFLD , and recipients with those factors should be monitored for NAFLD . Furthermore, possible progression to non‐alcoholic steatohepatitis ( NASH ) or fibrosis and metabolic syndrome should be considered in future studies.